Ernest V Pedapati
Overview
Explore the profile of Ernest V Pedapati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
844
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Norris J, De Stefano L, McKinney W, Schmitt L, Miyakoshi M, Gross C, et al.
medRxiv
. 2025 Feb;
PMID: 39973986
Background: Fragile X Syndrome (FXS) is a rare, neurodevelopmental disorder caused by a mutation to the Fragile X messenger ribonucleoprotein 1 () gene and characterized by sensory processing abnormalities and...
2.
Elmaghraby R, Blank E, Miyakoshi M, Gilbert D, Wu S, Larsh T, et al.
J Child Adolesc Psychopharmacol
. 2025 Jan;
PMID: 39792483
Autism spectrum disorder (ASD) is characterized by deficits in social behavior and executive function (EF), particularly in cognitive flexibility. Whether transcranial magnetic stimulation (TMS) can improve cognitive outcomes in patients...
3.
Smith E, Dominick K, Schmitt L, Pedapati E, Erickson C
J Neurodev Disord
. 2024 Dec;
16(1):69.
PMID: 39701935
Specialization of the brain for language is early emerging and essential for language learning in young children. Fragile X Syndrome (FXS) is a neurogenetic disorder marked by high rates of...
4.
McKinney W, Schmitt L, De Stefano L, Ethridge L, Norris J, Horn P, et al.
J Child Adolesc Psychopharmacol
. 2024 Dec;
PMID: 39651602
Treatment studies in knockout rodent models have found that minocycline and lovastatin each improve synaptic, neurological, and behavioral functioning, and open-label chronic dosing studies in human patients with fragile X...
5.
Ethridge L, Pedapati E, Schmitt L, Norris J, Auger E, De Stefano L, et al.
Sci Rep
. 2024 Oct;
14(1):22982.
PMID: 39362936
Recent failures translating preclinical behavioral treatment effects to positive clinical trial results in humans with Fragile X Syndrome (FXS) support refocusing attention on biological pathways and associated measures, such as...
6.
Fox N, Perez-Edgar K, Morales S, Brito N, Campbell A, Cavanagh J, et al.
Dev Cogn Neurosci
. 2024 Sep;
69:101447.
PMID: 39305603
The HEALthy Brain and Child Development (HBCD) Study, a multi-site prospective longitudinal cohort study, will examine human brain, cognitive, behavioral, social, and emotional development beginning prenatally and planned through early...
7.
Erickson C, Perez-Cano L, Pedapati E, Painbeni E, Bonfils G, Schmitt L, et al.
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062003
This study aimed to evaluate the safety and tolerability of STP1, a combination of ibudilast and bumetanide, tailored for the treatment of a clinically and biologically defined subgroup of patients...
8.
Larsh T, Gilbert D, Vadivelu S, Binder D, Pedapati E, Wu S
Mov Disord Clin Pract
. 2024 Jul;
11(10):1305-1307.
PMID: 38989718
No abstract available.
9.
Pedapati E, Ethridge L, Liu Y, Liu R, Sweeney J, DeStefano L, et al.
bioRxiv
. 2024 Jun;
PMID: 38915683
Fragile X syndrome (FXS) is an X-linked disorder that often leads to intellectual disability, anxiety, and sensory hypersensitivity. While sound sensitivity (hyperacusis) is a distressing symptom in FXS, its neural...
10.
Liu R, Pedapati E, Schmitt L, Shaffer R, Smith E, Dominick K, et al.
Biomark Neuropsychiatry
. 2024 May;
9.
PMID: 38817342
Objective: Fragile X Syndrome (FXS) is the leading monogenic cause of intellectual disability and autism spectrum disorder. Currently, there are no established biomarkers for predicting and monitoring drug effects in...